Table 3 Summary of the univariate analysis

Sex

P = 0.345

M

F

159(57.4%)

118(42.6%)

32(64.0%)

18(36.0%)

127(55.9%)

100(44.1%)

Median age

60.95 ± 12.48

68.50 ± 12.17

59.29 ± 11.95

P = 0.001

Comorbidities

High blood pressure

Diabetes

Chronic smoking

Dyslipidemia

75(27.1%)

39(14.1%)

58(20.9%)

34(12.3%)

27(54.0%)

14(28.0%)

12(24.0%)

9(18.0%)

48(21.1%)

25(11.0%)

46(20.3%)

25(11.0%)

P = 0.001

P = 0.003

P = 0.756

P = 0.231

Chronic alcoholism

37(13.4%)

4(8.0%)

33(14.5%)

P = 0.259

Psychiatric disease

18(6.5%)

8(16.0%)

10(4.4%)

P = 0.007

Cardiovascular diseases

24(8.7%)

8(16.0%)

16(7.0%)

P = 0.082

Respiratory disease

18(6.5%)

4(8.0%)

14(6.2%)

P = 0.750

Renal disease

8(2.9%)

4(8.0%)

4(1.8%)

P = 0.038

Treatment

diuretics

ACE inhibitors

Calcium channel blockers

angiotensin II receptor blockers

26(9.4%)

27(9.7%)

20(7.2%)

33(11.9%)

9(18.0%)

12(24.0%)

5(10.0%)

18(36.0%)

17(7.5%)

15(6.6%)

15(6.6%)

15(6.6%)

P = 0.037

P = 0.001

P = 0.545

P = 0.001

ASA score

P = 0.001

< 3

≥ 3

233(84.1%)

44(15.9%)

24(48.0%)

26(52.0%)

209(92.1%)

18(7.9%)

Neo adjuvant treatment

238(85.9%)

45(90%)

193(85%)

P = 0.386

Surgery

P = 0.741

Coelioscopic approach

Laparotomy approach

184(66.4%)

93(33.6%)

32(64.0%)

18(36.0%)

152(67.0%)

75(33.0%)

Post operative complications

P = 0.365

Clavien-Dindo classification

 1

 2

 3

27(9.7%)

12(4.4%)

23(8.4%)

4(8.0%)

2(4.0%)

5(10.0%)

23(10.2%)

10(4.4%)

18(7.9%)

Season of the procedure

P = 0.280

Autumn

Winter

Spring

Summer

74 (26,7%)

74 (26,7%)

90 (32,5%)

39 (14,1%)

12(24,0%)

10(20,0%)

22(44,0%)

6(12,0%)

62(27,3%)

64(28,2%)

68(30,0%)

33(14,5%)